Minority Health and Health Equity Archive
Permanent URI for this communityhttp://hdl.handle.net/1903/22236
Browse
26 results
Search Results
Item Racial differences in medication adherence: A cross-sectional study of Medicare enrollees.(2010) Gerber, Ben S; Cho, Young Ik; Arozullah, Ahsan M; Lee, Shoou-Yih DElderly African Americans reported that they followed physician instructions on how to take medications less frequently than did elderly whites, even after adjusting for differences in demographic characteristics, health literacy, depression, and social support.Item Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey.(2002) Nelson, Karin; Norris, Keith; Mangione, Carol MAfrican Americans and Mexican Americans were less likely to report serum cholesterol screening than whites. Even when identified as having high cholesterol that required medication, African Americans and Mexican Americans were less likely than whites to be taking cholesterol-lowering agents.Item Commentary on "Increasing Minority Participation in Clinical Research": A White Paper from The Endocrine Society(2007) Alexander-Bridges, M.; Doan, L. L.Underrepresentation of racial and ethnic minorities in clinical research limits the applicability of trial results to diverse subpopulations. Recognizing an ongoing need to increase participation by minorities, The Endocrine Society established a task force of thought leaders from all stakeholder groups—the pharmaceutical industry, federal agencies, academia, and community groups—to develop a white paper outlining recommendations for meeting this need. The primary goal is to ensure that clinical research supporting the safety and efficacy of pharmaceutical products and the validity of biomarkers used to design therapeutic strategies is based on statistically powered data derived from minority subpopulations. To realize…Item Increasing Minority Participation in Clinical Research(2007) Agodoa, Lawrence; Alanis, Alfonso J.; Alexander-Bridges, Maria; Doan, Loretta L.; Fleming, G. Alexander; Getz, Ken; Gibbs, Brian K.; Prothrow-Stith, DeborahOur goal is to ensure that clinical research supporting 1) the safety and efficacy of products for labeling purposes and 2) the validity of biomarkers commonly used to assess risk and to design therapeutic strategies is based on data sufficient for statistical power and derived from diverse subpopulations. It is widely recognized that data supporting therapeutic options for women and minorities have been deficient because these groups were not previously included in clinical trials. Although the combined efforts of Congress, the Office of Women’s Health at the Food and Drug Administration (FDA), and the Office of Research on Women’s Health…Item Race and Nicotine Replacement Treatment Outcomes Among Low-Income Smokers(2008) Fu, Steven S.; Burgess, Diana J.; Hatsukami, Dorothy K.; Noorbaloochi, Siamak; Clothier, Barbara A.; Nugent, Sean; van Ryn, MichelleAbstract available at publisher's web site.Item Racial/Ethnic Disparities in the Use of Nicotine Replacement Therapy and Quit Ratios in Lifetime Smokers Ages 25 to 44 Years(2008) Fu, S. S.; Kodl, M. M.; Joseph, A. M.; Hatsukami, D. K.; Johnson, E. O.; Breslau, N.; Wu, B.; Bierut, L.Abstract available at publisher's web site.Item Latinos report less use of pharmaceutical aids when trying to quit smoking(2004) Levinson, Arnold H; Pérez-Stable, Eliseo J; Espinoza, Paula; Flores, Estevan T; Byers, Tim EAbstract available at publisher's web site.Item Sustained-Release Bupropion for Smoking Cessation in African Americans: A Randomized Controlled Trial(2002) Ahluwalia, J. S.Abstract available at publisher's web site.Item Pharmacotherapeutic disparities: Racial, ethnic, and sex variations in medication treatment(2010) Hall-Lipsy, E. A.; Chisholm-Burns, M. A.Abstract available at publisher's web site.Item Racial/Ethnic Differences in Concerns About Current and Future Medications Among Patients With Type 2 Diabetes(2008) Huang, E. S.; Brown, S. E.S.; Thakur, N.; Carlisle, L.; Foley, E.; Ewigman, B.; Meltzer, D. O.OBJECTIVE—To evaluate ethnic differences in medication concerns (e.g., side effects and costs) that may contribute to ethnic differences in the adoption of and adherence to type 2 diabetes treatments.RESEARCH DESIGN AND METHODS—We conducted face-to-face interviews from May 2004 to May 2006 with type 2 diabetic patients ≥18 years of age (N = 676; 25% Latino, 34% non-Hispanic Caucasian, and 41% non-Hispanic African American) attending Chicago-area clinics. Primary outcomes of interest were concerns regarding medications and willingness to take additional medications.RESULTS—Latinos and African Americans had higher A1C levels than Caucasians (7.69 and 7.54% vs. 7.18%, respectively; P < 0.01). Latinos and African Americans were more likely than Caucasians to worry about drug side effects (66 and 49% vs. 39%, respectively) and medication dependency (65 and 52% vs. 39%, respectively; both P < 0.01). Ethnic minorities were also more likely to report reluctance to adding medications to their regimen (Latino 12%, African American 18%, and Caucasian 7%; P < 0.01). In analyses adjusted for demographics, income, education, and diabetes duration, current report of pain/discomfort with pills (odds ratio 2.43 [95% CI 1.39–4.27]), concern regarding disruption of daily routine (1.97 [1.14–3.42]), and African American ethnicity (2.48 [1.32–4.69]) emerged as major predictors of expressed reluctance to adding medications.CONCLUSIONS—Latinos and African Americans had significantly more concerns regarding the quality-of-life effects of diabetes-related medications than Caucasians. Whether these medication concerns contribute significantly to differences in treatment adoption and disparities in care deserves further exploration.
- «
- 1 (current)
- 2
- 3
- »